Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 pseudogene (ENSG00000225460, also referred to as LOC124902324) is a **pseudogene**, which is a nonfunctional segment of DNA that resembles functional ubiquitin-conjugating enzyme E2 genes. Pseudogenes arise by gene duplication or retrotransposition events and accumulate mutations that disable their ability to code for a functional protein[2][8][6]. Ubiquitin-conjugating enzymes (E2 enzymes) are responsible for the ubiquitination of proteins, playing a role in targeting proteins for degradation by the proteasome[1]. However, this particular locus does not produce an active enzyme or participate in the ubiquitination pathway[2][8][6]. Pseudogenes are generally not considered therapeutic targets, though some pseudogenes elsewhere in the genome have been found to carry regulatory roles via RNA-level effects, these are the exception rather than the rule and require specific evidence not provided for this locus[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 pseudogene.